LSTA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2005, for Phase III Medical, Inc. (Note: The input metadata lists "Lisata Therapeutics," but the filing text explicitly identifies the registrant as Phase III Medical, Inc.). The Company operates in two segments: the "run off" of its former internet-based extended warranty business and a new venture providing capital and guidance to healthcare and life sciences companies in exchange for royalty interests. As of the reporting date, the Company has not received royalty payments from its new business initiatives.

Key Financial Metrics

Debt and Liquidity: The Company holds $547,000 in notes payable and $492,801 in accrued dividends on Series A preferred stock. Cash balances dropped from $27,868 to $5,379 during the quarter.

Material Changes vs. Prior Period

• Revenue Decline: Earned revenues decreased by approximately 61% to $10,535, driven by the natural run-off of the warranty business with no new royalty revenue recognized.
• Reduced Net Loss: Net loss improved significantly to $(249,670) from $(456,206) in the prior year quarter. This improvement was primarily due to the absence of a $240,000 expense for the purchase of medical royalty streams recorded in Q1 2004 and reduced interest expenses.
• Increased Operating Expenses: Selling, general, and administrative (SG&A) expenses rose by approximately $66,000 to $215,501, attributed to increased payroll ($73,000) and investor relations costs ($15,000).
• Debt Conversion: A $100,000 convertible note held by the Chief Operating Officer was converted into 1,960,784 shares of common stock in February 2005, reducing debt obligations.

Outlook, Risks, and Management Commentary

Going Concern Uncertainty: Management explicitly states that the financial statements are prepared assuming the Company will continue as a going concern. However, the Company has limited financial resources, no current operations generating significant cash flow, and substantial doubt exists regarding its ability to meet current obligations without additional financing.

Liquidity Strategy: The Company relies on proceeds from the sale of promissory notes and common stock to fund operations. In Q1 2005, it raised $72,000 via notes payable. Management plans to continue raising capital through equity and debt sales to accredited investors.

Commitments: The Company has a contractual commitment to pay Parallel Solutions, Inc. (PSI) up to an additional $194,676 for the development of bioshielding technology. Additionally, cumulative unpaid dividends on Series A preferred stock total $492,801.

Subsequent Events: Following the quarter end, the Company engaged an investment banker for a proposed private placement of convertible notes and warrants and entered into an employment agreement with a new Executive Vice President and General Counsel involving a $100,000 stock purchase and promissory note.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5,379 cash balance against immediate liabilities, including $1.4 million in current liabilities and $492,801 in accrued preferred dividends.
• Debt Maturity: Confirm the status of the $547,000 in notes payable, many of which have been extended past original due dates, and assess the risk of default or further dilution.
• Capital Raising: Monitor the progress of the proposed private placement of convertible notes and warrants announced in April 2005 to determine if the Company can secure necessary funding.
• Royalty Revenue: Assess the timeline for potential revenue recognition from the Parallel Solutions, Inc. agreement, noting that $720,000 has been invested with zero revenue to date.
• Dilution Risk: Review the impact of recent and planned stock issuances (including 1.96 million shares issued in Q1 and 1.67 million shares in a subsequent event) on existing shareholder equity.